Abstract Body

Background

Tenofovir+lamivudine+dolutegravir (TLD) has considerably improved the achievement of viral suppression (<1000 copies/ml), with an increased proportion of recipients of care (RoC) in the range of low-level viremia (50-999 copies/ml). Of note, persistent low-level viraemia (pLLV) may indicate suboptimal adherence or emerging drug resistance, which are major causes of treatment failure. This study assessed the burden and determinants of pLLV among RoC on TLD as first-line regimen in Cameroon.

Methods

We conducted a retrospective cohort analysis among RoC on TLD monitored for HIV plasma viral load (PVL) between January 2022 and August 2025 at the Chantal BIYA International Reference Centre (CIRCB), Yaoundé. Eligible patients were those with ≥2 consecutive PVL results during follow-up; those with treatment interruption or missing consecutive measures were excluded. pLLV was defined as ≥2 PVL between 50–999 copies/mL over ≥6 months. Baseline PVL was categorized as 50–200 vs 201–999 copies/mL. Logistic regression was used to identify factors independently associated with pLLV, with p<0.05 considered as statistically significant.

Results

A total of 975 RoC on TLD experiencing LLV were included (66.7% female, 93.3% adults). At baseline, median PVL was 90 [60-173] copies/ml; 77.1% (751/975) had PVL 50-200 copies/ml and 22.9% (223/975) 201-999 copies/ml. The overall burden of pLLV was 77.5%, with a median duration of 18 [12-24] months. Stratified by treatment duration, pLLV prevalence was 81.6% (31/38) at 6–12 months, 82.1% (207/252) at 13–24 months, 80.1% (363/453) at 25–45 months, and 66.7% (154/231) beyond 45 months on TLD, (p<0.0001). The burden of pLLV was similar by sex (77.7% in female vs 77.2% male, OR: 0.9; p=0.95), but significantly higher among children/adolescents (88.7%; OR: 2.4; p=0.03). At baseline, RoC with PVL 201–999 copies/mL were more likely to experience pLLV (84.3% vs 76.1%, OR 1.7; p=0.006). After multivariable adjustment, only baseline PVL 201–999 copies/mL remained independently associated with pLLV (aOR 1.74; 95% CI: 1.1–2.5; p=0.007).

Conclusions

In spite of the encouraging viral suppression in the TLD-era, pLLV remains concerning among RoC in Cameroon, driven essentially by baseline viremia between 201–999 copies/mL. Thus, achieving epidemic control would require integrating pLLV surveillance into HIV programs. This will ensure a sustained treatment effectiveness, guide timely interventions, and mitigate emerging resistance to TLD in low- and middle-income countries.